The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Do special access programs facilitate off-label prescribing? The experience of enzalutamide in prostate cancer.
Nimira S. Alimohamed
No relevant relationships to disclose
Raya Leibowitz-Amit
No relevant relationships to disclose
Arnoud J. Templeton
No relevant relationships to disclose
Jo-An Seah
No relevant relationships to disclose
Francisco Emilio Vera-Badillo
No relevant relationships to disclose
Anthony M. Joshua
Consultant or Advisory Role - Astex Therapeutics (U)
Jennifer J. Knox
No relevant relationships to disclose
Ian Tannock
No relevant relationships to disclose
Srikala S. Sridhar
Consultant or Advisory Role - Astellas Pharma
Honoraria - Astellas Pharma